-
CASH 2026 Professor Erlie Jiang: Four Decades of Continuity and Innovation — The “Tianjin Model” Pioneering a New Era in Hematopoietic Stem Cell Transplantation
The “Tianjin Model” of hematopoietic stem cell transplantation (HSCT) is a distinctive transplant system that integrates standardization, precision, and innovation. It has been progressively developed through nearly four decades of continuous exploration and generational knowledge transfer at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (also known as the Tianjin…
-
Lymphoma Roundtable · ASH Special Professor Qingqing Cai: New Advances in Bispecific Antibody Therapy for Relapsed/Refractory Lymphoma
The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) was recently successfully held in Orlando, United States. As the year’s flagship event in hematology, the meeting presented a concentrated series of groundbreaking advances in lymphoma research, offering new directions for the optimization of clinical practice.
-
Professor Sujun Han: 2026 NCCN Guideline Update — Urothelial Carcinoma Enters an Era of Precision Medicine and Organ PreservationBeijing Academic Exchange Conference for Young Physicians in Urologic Oncology
At the beginning of 2026, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was grandly held in Beijing. The meeting focused on frontier advances and standardized practices in urologic oncology and brought together numerous domestic experts and scholars in the field.
-
Professor Hailiang Zhang Provides an In-Depth Interpretation of the 2026 NCCN Kidney Cancer Guideline Updates: What New Clinical Insights Arise from the Elevated Role of Radiotherapy and Optimized Immunotherapy Stratification?
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on cutting-edge topics in the diagnosis and treatment of urologic malignancies, aiming to establish a high-level academic exchange platform and to promote innovation in clinical thinking and standardized practice among young physicians.
-
Professor Yige Bao: From “New Leaves Spur the Old” to “One Mountain Opens, Another Blocks the Way” —Reflections and Challenges in Post-Neoadjuvant Management of MIBC
Recently, the Beijing Academic Exchange Conference for Young Physicians in Urologic Oncology was successfully held in Beijing. The meeting focused on the latest frontiers in urologic oncology and brought together many leading mid-career and young experts from across China, aiming to elevate clinical practice through intellectual exchange.
-
ESMO Hot Topic Focus | Professor Richard S. Finn: Immunotherapy-Based Combinations Turn “Stone into Gold” — The TALENTOP Study Reshapes the Treatment Landscape of Advanced HCC
In the global field of hepatocellular carcinoma (HCC) treatment, the synergistic use of targeted therapy and immunotherapy has led to breakthrough progress, significantly prolonging survival for patients with advanced disease and bringing renewed hope to countless individuals. Yet medical progress never stands still. How to further transcend existing treatment paradigms and unlock deeper survival benefits…
-
ESMO International Perspective | Professor Maria Reig: Large International Multicenter Evidence Supports the Inclusion of EBRT in the BCLC Staging and Treatment Algorithm
The Barcelona Clinic Liver Cancer (BCLC) staging system is the cornerstone framework guiding treatment decisions for hepatocellular carcinoma (HCC). Its fundamental role lies in stratifying patients according to three key prognostic determinants—tumor burden, liver function, and performance status—thereby aligning prognosis assessment with evidence-based treatment recommendations for each disease stage.
-
ESMO International Perspective | 42-Month Long-Term Follow-Up with Median OS of 22.8 Months: Professor Manon Allaire Interprets the Outstanding Real-World Performance of the “T+A” Regimen
The combination of atezolizumab plus bevacizumab (the “T+A” regimen) has established a new standard of care for first-line treatment of advanced hepatocellular carcinoma (HCC). However, the lack of long-term survival data and uncertainties regarding its effectiveness in complex real-world populations have remained major clinical concerns.
Connecting Medical Expertise through Media